These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26249845)

  • 1. Acute or chronic use of lacosamide does not alter its distribution between serum and cerebrospinal fluid.
    Michelhaugh SK; Basha M; Rhoney DH; Shah AK; Mittal S
    Epilepsia; 2015 Nov; 56(11):1732-7. PubMed ID: 26249845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of lacosamide concentrations in cerebrospinal fluid and serum in patients with epilepsy.
    May TW; Brandt C; Helmer R; Bien CG; Cawello W
    Epilepsia; 2015 Jul; 56(7):1134-40. PubMed ID: 25988882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs.
    Markoula S; Teotonio R; Ratnaraj N; Duncan JS; Sander JW; Patsalos PN
    Ther Drug Monit; 2014 Aug; 36(4):494-8. PubMed ID: 24562047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
    Contin M; Albani F; Riva R; Candela C; Mohamed S; Baruzzi A
    Ther Drug Monit; 2013 Dec; 35(6):849-52. PubMed ID: 23942540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy.
    Rambeck B; Jürgens UH; May TW; Pannek HW; Behne F; Ebner A; Gorji A; Straub H; Speckmann EJ; Pohlmann-Eden B; Löscher W
    Epilepsia; 2006 Apr; 47(4):681-94. PubMed ID: 16650134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on lacosamide: a retrospective study on the relationship between serum concentration, dosage, and adverse events.
    Hillenbrand B; Wisniewski I; Jürges U; Steinhoff BJ
    Epilepsy Behav; 2011 Nov; 22(3):548-51. PubMed ID: 21962950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive lacosamide in clinical practice: sodium blockade with a difference?
    Stephen LJ; Kelly K; Parker P; Brodie MJ
    Epilepsy Behav; 2011 Nov; 22(3):499-504. PubMed ID: 21890421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive lacosamide--5 years' clinical experience.
    Stephen LJ; Kelly K; Parker P; Brodie MJ
    Epilepsy Res; 2014 Oct; 108(8):1385-91. PubMed ID: 25064538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions--first clinical experience.
    Sattler A; Schaefer M; May TW; Rambeck B; Brandt C
    Epilepsy Res; 2011 Aug; 95(3):207-12. PubMed ID: 21543186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous lacosamide in clinical practice-Results from an independent registry.
    Lang N; Lange M; Schmitt FC; Bös M; Weber Y; Evers S; Burghaus L; Kellinghaus C; Schubert-Bast S; Bösel J; Lammers T; Sabolek M; van Baalen A; Dziewas R; Kraft A; Ruf S; Stephani U
    Seizure; 2016 Jul; 39():5-9. PubMed ID: 27161669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Dose and Antiepileptic Comedication on Lacosamide Serum Concentrations in Patients With Epilepsy of Different Ages.
    May TW; Helmer R; Bien CG; Brandt C
    Ther Drug Monit; 2018 Oct; 40(5):620-627. PubMed ID: 30086089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures.
    Fountain NB; Krauss G; Isojarvi J; Dilley D; Doty P; Rudd GD
    Epilepsia; 2013 Jan; 54(1):58-65. PubMed ID: 22708895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience of intravenous lacosamide in infants and young children.
    Arkilo D; Gustafson M; Ritter FJ
    Eur J Paediatr Neurol; 2016 Mar; 20(2):212-217. PubMed ID: 26810009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous Lacosamide in refractory nonconvulsive status epilepticus.
    Mnatsakanyan L; Chung JM; Tsimerinov EI; Eliashiv DS
    Seizure; 2012 Apr; 21(3):198-201. PubMed ID: 22244046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous lacosamide in status epilepticus: Correlation between loading dose, serum levels, and clinical response.
    Perrenoud M; André P; Alvarez V; Stähli C; Decosterd LA; Rossetti AO; Novy J
    Epilepsy Res; 2017 Sep; 135():38-42. PubMed ID: 28622537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in epilepsy treatment: lacosamide pharmacokinetic profile.
    Cawello W; Stockis A; Andreas JO; Dimova S
    Ann N Y Acad Sci; 2014 Nov; 1329():18-32. PubMed ID: 25167889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the correlations of lacosamide concentrations in saliva and serum in patients with epilepsy.
    Brandt C; Bien CG; Helmer R; May TW
    Epilepsia; 2018 Apr; 59(4):e34-e39. PubMed ID: 29450894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic Variability, Efficacy and Tolerability.
    Svendsen T; Brodtkorb E; Baftiu A; Burns ML; Johannessen SI; Johannessen Landmark C
    Neurochem Res; 2017 Jul; 42(7):2077-2083. PubMed ID: 28349359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures.
    de Biase S; Valente M; Gigli GL; Merlino G
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):997-1005. PubMed ID: 28750560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saliva and serum lacosamide concentrations in patients with epilepsy.
    Greenaway C; Ratnaraj N; Sander JW; Patsalos PN
    Epilepsia; 2011 Feb; 52(2):258-63. PubMed ID: 20946125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.